Kamada Ltd.
Kamada Ltd. (KMDA) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · KMDA · as of Jun 8, 2026
Key Statistics
Explore Kamada Ltd. Data
kmda stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 6 · Buy rate: 83.3%
The KMDA analyst consensus is Buy, based on ratings from 6 Wall Street analysts over the past 3 months. The average 12-month price target is $12.00, representing +65.73% upside from the current price of $7.24.
Competitors & Peers
kmda competitorsKMDA
AUNA
EOLS
GALT
PRTC
QSIStock Performance
Full HistoryAbout Kamada Ltd.
Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGA…
what is kamada ltd. · kmda stock overview · kamada ltd. company profile · who is kamada ltd. ceo · kmda NASDAQ · kamada ltd. headquarters · kamada ltd. business segments
About Stock Overview & Key Data
Kamada Ltd. (KMDA) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry, listed on NASDAQ since May 31, 2013. As of the latest trading session, KMDA stock price is $7.24, with a market capitalization of $417.7M. The stock has returned +3.89% over the past 12 months and +2.56% year-to-date.
According to 6 Wall Street analysts, the consensus rating for Kamada Ltd. stock is Buy, with an average 12-month price target of $12.00. In fiscal year 2025, Kamada Ltd. reported revenue of $180.5M and net income of $20.2M. For detailed data — including Kamada Ltd. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Kamada Ltd. (KMDA) stock price is $7.24. The stock is traded on NASDAQ under the ticker symbol KMDA. The 52-week range is $6.50 – $9.35.